The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
Florian Heidel
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Vincent Ribrag
No relevant relationships to disclose
Alessandro M. Vannucchi
Consultant or Advisory Role - Novartis
Jean-Jacques Kiladjian
Consultant or Advisory Role - Novartis; Sanofi
Research Funding - Novartis
Francesco Passamonti
Consultant or Advisory Role - Novartis
Amjad Hayat
No relevant relationships to disclose
Eibhlin Conneally
Honoraria - Novartis
Other Remuneration - Novartis
Thomas Kindler
Consultant or Advisory Role - Novartis
Bruno Martino
No relevant relationships to disclose
Daniel B Lipka
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Suddhasatta Acharyya
Employment or Leadership Position - Novartis
Florence Binlich
Employment or Leadership Position - Novartis
Tracy Liu
Employment or Leadership Position - Novartis
Song Mu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Claire N. Harrison
Honoraria - Gilead Sciences; Novartis; Sanofi ; Shire
Research Funding - Novartis